zip >>> 94901
sector >>> Healthcare
fullTimeEmployees >>> 3001
longBusinessSummary >>> BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
city >>> San Rafael
phone >>> 415 506 6700
state >>> CA
country >>> United States
companyOfficers >>> []
website >>> http://www.biomarin.com
maxAge >>> 1
address1 >>> 770 Lindaro Street
industry >>> Biotechnology
previousClose >>> 76.58
regularMarketOpen >>> 76.46
twoHundredDayAverage >>> 98.463524
trailingAnnualDividendYield >>> None
payoutRatio >>> 0
volume24Hr >>> None
regularMarketDayHigh >>> 77.96
navPrice >>> None
averageDailyVolume10Day >>> 2671828
totalAssets >>> None
regularMarketPreviousClose >>> 76.58
fiftyDayAverage >>> 84.61441
trailingAnnualDividendRate >>> None
open >>> 76.46
toCurrency >>> None
averageVolume10days >>> 2671828
expireDate >>> None
yield >>> None
algorithm >>> None
dividendRate >>> None
exDividendDate >>> None
beta >>> 0.788182
circulatingSupply >>> None
startDate >>> None
regularMarketDayLow >>> 75.835
priceHint >>> 2
currency >>> USD
trailingPE >>> 114.48225
regularMarketVolume >>> 1736101
lastMarket >>> None
maxSupply >>> None
openInterest >>> None
marketCap >>> 14034676736
volumeAllCurrencies >>> None
strikePrice >>> None
averageVolume >>> 2354676
priceToSalesTrailing12Months >>> 7.598247
dayLow >>> 75.835
ask >>> 78.9
ytdReturn >>> None
askSize >>> 1100
volume >>> 1736101
fiftyTwoWeekHigh >>> 131.95
forwardPE >>> 179.97675
fromCurrency >>> None
fiveYearAvgDividendYield >>> None
fiftyTwoWeekLow >>> 62.88
bid >>> 76.13
tradeable >>> False
dividendYield >>> None
bidSize >>> 800
dayHigh >>> 77.96
exchange >>> NMS
shortName >>> BioMarin Pharmaceutical Inc.
longName >>> BioMarin Pharmaceutical Inc.
exchangeTimezoneName >>> America/New_York
exchangeTimezoneShortName >>> EDT
isEsgPopulated >>> False
gmtOffSetMilliseconds >>> -14400000
quoteType >>> EQUITY
symbol >>> BMRN
messageBoardId >>> finmb_25605
market >>> us_market
annualHoldingsTurnover >>> None
enterpriseToRevenue >>> 7.664
beta3Year >>> None
profitMargins >>> 0.06619
enterpriseToEbitda >>> 144.586
52WeekChange >>> 0.14821959
morningStarRiskRating >>> None
forwardEps >>> 0.43
revenueQuarterlyGrowth >>> None
sharesOutstanding >>> 181350000
fundInceptionDate >>> None
annualReportExpenseRatio >>> None
bookValue >>> 17.868
sharesShort >>> 10302338
sharesPercentSharesOut >>> 0.056799997
fundFamily >>> None
lastFiscalYearEnd >>> 1577750400
heldPercentInstitutions >>> 0.99303
netIncomeToCommon >>> 122258000
trailingEps >>> 0.676
lastDividendValue >>> None
SandP52WeekChange >>> 0.108078
priceToBook >>> 4.331207
heldPercentInsiders >>> 0.00495
nextFiscalYearEnd >>> 1640908800
mostRecentQuarter >>> 1593475200
shortRatio >>> 2.88
sharesShortPreviousMonthDate >>> 1596153600
floatShares >>> 180087404
enterpriseValue >>> 14155790336
threeYearAverageReturn >>> None
lastSplitDate >>> None
lastSplitFactor >>> None
legalType >>> None
morningStarOverallRating >>> None
earningsQuarterlyGrowth >>> None
dateShortInterest >>> 1598832000
pegRatio >>> 0.39
lastCapGain >>> None
shortPercentOfFloat >>> 0.065
sharesShortPriorMonth >>> 9957195
category >>> None
fiveYearAverageReturn >>> None
regularMarketPrice >>> 76.46
logo_url >>> https://logo.clearbit.com/biomarin.com
